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Abstract
Background: Aspirin-intolerant asthma (AIA) occurs in the lower and upper airways through excessive production
of leukotrienes upon administration of non-steroidal anti-inflammatory drugs (NSAIDs). One of the three symptoms
of AIA is nasal polyposis, a chronic inflammatory disease that is related to the function of calcium ion in
recruitment of immune cells during airway inflammation. It has been implicated that bronchodilation in the airway
is related to Ca(2+) regulation. The calcium channel, voltage-dependent, gamma subunit 6 (CACNG6) gene encodes a
protein that stabilizes the calcium channel.
Methods: To study the associations between AIA and polymorphisms in CACNG6 gene, eight variants were
genotyped in 102 AIA cases and 429 aspirin-tolerant asthma (ATA) controls. Logistic analyses were used to evaluate
the associations of CACNG6 polymorphisms with AIA.
Results: Statistical analyses revealed that a single nucleotide polymorphism (SNP; rs192808C > T; P = 0.0004, P
corr =
0.0029, OR = 2.88 in co-dominant model; P = 0.0005, P
corr = 0.0036, OR = 2.99 in dominant model) in intron and a
haplotype unique to this variant (CACNG6_BL1_ht6; P = 0.003, P
corr = 0.02, OR = 2.57 in co-dominant model, P =
0.001, P
corr = 0.0087, OR = 2.81 in dominant model) were significantly associated with the risk of AIA.
Conclusions: Our results suggest that the CACNG6 variants might be associated with the risk of AIA in a Korean
population.
Background
Aspirin-intolerant asthma (AIA), which was first
described in 1922, is a unique clinical syndrome
associated with acute bronchconstriction upon adminis-
tration of aspirin and other non-steroidal anti-inflamma-
tory drugs [1]. Although considered as one of the most
widely used medication, aspirin intake also incurs var-
ious side effects including manifested gastrointestinal
ulcer, stomach bleeding and tinnitus especially in higher
doses. Although the side effects caused by aspirin are
not common, these effects have been reported in about
10% of adult asthmatics.
The triad of AIA symptoms includes aspirin sensitiv-
ity, bronchial asthma and chronic rhinosinusitis with
nasal polyposis [2-4]. Nasal polyposis is a chronic
inflammatory disease of the upper respiratory tract that
affects around two thirds of patients with AIA. The
polyps are filled with mast cells and eosinophils due to
high levels of the proinflammatory cysteinyl leukotrienes
(cysLTs) [5]. After mast cells are activated, it releases a
variety of paracrine signals that target tissues such as
bronchi and vasculature to recruit other immune cells
at the inflammatory site. Among the remarkable signal-
ing molecules released by mast cells, the cysLTs that
includes leukotriene C(4) (LTC4), LTD4, and LTE4 are
well known [6,7]. The LTC4 is secreted from mast cells
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release-activated calcium (CRAC) channels [7-10]. It has
also been reported that proteinase activated receptor-2
(PAR2), as a novel emerging pharmacological target in
airway diseases, is expressed in the airway epithelium
and its activation may be involved in the protective role
of preserving bronchial functionality [11,12]. In line with
the fact that the airway smooth muscle cell contraction
is regulated by changes in intracellular Ca(2+) concen-
tration, a previous molecular report has revealed a rela-
tionship between this Ca(2+) regulation and
bronchodilation in the airway [13]. More recently, novel
actions of NSAIDs on vascular ion channels including
L-type calcium channel has also been suggested [14].
The L-type calcium channels are composed of five
subunits. The CACNG6 gene encodes one of these sub-
units, specifically a gamma subunit protein which was
first identified in muscle cells [15]. Recent studies have
revealed negative relations of CACNG6 gene expression
to chronic obstructive pulmonary disease, responses of
the human airway epithelium following injury and %
parenchyma in lung tissues [16,17]. The CACNG6 is an
integral membrane protein that stabilizes the calcium
channel during its inactive state [18]. Since the role of
azelastine in asthma treatment is achieved by blocking
the L-type calcium channel thus, preventing Ca(2+) cur-
rent [19], the CACNG6 may, therefore, be of interest in
the study of asthma treatment. Moreover, abnormal
Ca(2+) influx may induce leukotriene overproduction
from mast cells, leading to recruitment of other immune
cells, such as eosinophils, resulting in vasospasm by
eosinophilic infiltration of the coronary artery wall and
cardiac contractility [8,20]. Although many signaling
pathways have been known to underlie the reversible
contraction of airway smooth muscle, ionic mechanisms
related to Ca(2+) and the calcium channels in the air-
ways are still poorly understood [21]. In this connection,
we explored whether CACNG6 single nucleotide poly-
morphisms (SNPs) are associated with AIA.
Methods
Study Subjects
Subjects in this study were recruited from the Asthma
Genome Research Center comprising hospitals of Soon-
chunhyang, Chunnam, Chungbuk, Seoul National and
Chung-Ang Universities in Korea. All subjects provided
written informed consents and the study protocols were
approved by the Institutional Review Board of each hos-
pital. Diagnosis of AIA was performed according to a
modified method as previously described [22]. We also
performed aspirin challenge in subjects with a history of
aspirin hypersensitivity, presence of urticaria, nasal
polyps and sinusitis. The AIA case group included
patients with 20% or greater decreases in FEV1 or 15%
to 19% decreases in FEV1 with naso-ocular or cutaneous
reactions, whereas subjects showing a rate of FEV1
decline less than 15% without extrabronchial, nasal or
skin symptoms were included in ATA group.
SNP selection and genotyping
We selected 8 common polymorphic SNPs from the
International HapMap Project phase 1&2 http://hapmap.
ncbi.nlm.nih.gov/ and National Center for Biotechnology
Information (build 36) based on the minor allele fre-
quency (> 0.05) and LD status. Among three SNPs
(rs3810244, rs158194, rs4806481)i nL D( | D ’| > 0.7), the
most common SNP (rs4806481) was selected for geno-
typing. For examination of AIA risk association, we gen-
otyped 8 common SNPs in the CACNG6 gene.
Genotyping was carried out with 20 ng of genomic
DNA by TaqMan assay in the ABI prism 7900HT
sequence detection system software version 2.3 (Applied
Biosystems, CA, USA) in 102 AIA cases and 429 ATA
controls with the assessment of data quality by duplicate
DNAs (n = 10). A total of 8 polymorphisms on
CACNG6 were successfully genotyped.
Statistics
We calculated linkage disequilibrium to all pairs of bialle-
lic loci using Lewontin’sD ’ (|D’|) [23] and r
2.P H A S Ea l g o -
rithm (ver. 2.0) developed by Stephens et al. was used for
inferring haplotypes [24]. Associations of genotypes and
haplotypes in the CACNG6 gene with AIA were calculated
using logistic analyses adjusted for age, gender, smoking
status, atopy and body mass index as covariates. We also
performed linear regression analysis to determine the dif-
ferences in the rates of decline in FEV1 following aspirin
challenge among the genotypes and haplotypes. The data
were adjusted, managed and analyzed using SAS version
9.1 (SAS Inc., Cary, NC). The effective number of inde-
pendent marker loci (7.28) was calculated for multiple
testing corrections using SNPSpD software http://genepi.
qimr.edu.au/general/daleN/SNPSpD/, which is based on
the spectral decomposition (SpD) of matrices of pair-wise
LD between SNPs.
Results
In this study, the clinical characteristics of the study
subjects showed that the fall rate by aspirin provocation
in AIA patients was significantly higher than that of
ATA controls (33.59 ± 13.42% vs. 3.54 ± 4.85%, respec-
tively; P < 0.0001). This was in contrast to the current
smoker ratio and mean age which was higher in ATA
controls than those of AIA patients (21.36% vs. 30.07%
for smoking status and 42.76 year vs. 47.30 year for
mean age, respectively). Body mass index (BMI) and
PC20 methacholine test also showed significant signals
(P < 0.01). In addition, AIA patients were more sensitive
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mg/ml). Analyses on other factors in subject’s clinical
characteristics showed no significant differences between
AIA and ATA groups. The clinical characteristics of the
study subjects are summarized in Table 1.
To investigate the association of CACNG6 polymorph-
isms with AIA, 8 SNPs (rs251850, rs4806481, rs158196,
rs158199, rs192808, rs450227, rs2291068, rs459247)i n
the CACNG6 gene were genotyped in a total of 531
study subjects including 102 AIA patients as a case
group and 429 ATA patients as controls. The genotype
distributions of all loci were in Hardy-Weinberg equili-
brium (Table 2, P > 0.05). Genetic map and location of
CACNG6 polymorphisms are shown in Fig. 1A. Logistic
analysis was used to analyze whether the genetic poly-
morphisms were associated with AIA. Interestingly, ana-
lysis revealed that a SNP in intron (rs192808C > T;O R
= 2.88, 95% CI = 1.60-5.17, P = 0.0004, P
corr = 0.0029 in
co-dominant model), which was more frequent in AIA
patients than in ATA controls (0.103 in AIA patients
and 0.045 in ATA patients) (Table 2), was significantly
associated with the risk of AIA even after multiple test-
ing corrections. In additional analysis using effective
models, this allelic variant also showed a susceptibility
to AIA in dominant model (OR = 2.99, 95% CI = 1.62-
5.54, P = 0.0005, P
corr = 0.0036).
Based on the 8 polymorphisms, haplotypes were calcu-
lated using PHASE software resulting in two haplotype
blocks (Fig. 1B and 1C). Although a different pattern in
Block 1 between AIA and ATA was observed (Fig. 1D),
the haplotypes which were composed of five SNPs were
used for the association analysis because they were esti-
mated as common haplotypes derived from a large
number of subjects in the Korean population. Among
the haplotypes, CACNG6_BL1_ht6, the only one con-
taining the rare T variant of rs192808,a l s os h o w e ds i g -
nificant association with risk of AIA (P = 0.003, P
corr =
0.02 in co-dominant model; P =0 . 0 0 1 ,P
corr =0 . 0 0 8 7i n
dominant model), showing a similar pattern with the
association of rs192808 S N P( T a b l e2 ) .I nt h ec a s eo f
CACNG6_BL1_ht6 haplotype, the frequency of AIA
p a t i e n t sw a sh i g h e ra ta b o u tt w o - f o l dt h a nt h a to fA T A
controls (0.093 and 0.045, respectively).
Next, we performed regression analysis for the asso-
ciation between decline of FEV1 by aspirin provocation
and CACNG6 polymorphisms. As summarized in Table
3, among all the variants and haplotypes, SNP rs192808
(P = 0.006 in co-dominant model and P = 0.01 in domi-
nant model) and haplotype CACNG6_BL1_ht6 (P = 0.03
in co-dominant model and P = 0.02 in dominant model)
showed the most significant signal. In addition, in the
second LD block, haplotype CACNG6_BL2_ht2 showed
an association with the decline of FEV1 by aspirin pro-
vocation in the dominant model (P = 0.03). However, in
further regression analysis using only AIA cases, no sig-
nificant associations were detected (Additional file 1,
Table S1), indicating that rs192808 and haplotypes of
CACNG6 could not directly affect the aspirin-induced
decline of FEV1 in AIA patients.
Discussion
Although over-production of pro-inflammatory cysLTs
such as LTC4, LTD4 and LTE4 has been considered as
a main cause of aspirin hypersensitivity in asthma [25],
recent studies have suggested that other genes may be
related to AIA [21,26,27]. On the other hand, previous
studies have reported that concentration of calcium ion
is related with leukotriene secretion [28] and that
CACNG6 gene is negatively expressed in chronic
obstructive pulmonary disease and human airway
epithelium following injury [16,17]. Considering these
facts, we hypothesized that the modulation of calcium
concentration could play an important role in abnormal
signaling pathways in the airways and that the CACNG6
gene, as a subunit of L-type calcium channels, and its
polymorphisms might be associated with risk of AIA.
Although the minor T allele of rs192808 and its unique
haplotype (CACNG6_BL1_ht6)s h o w e ds i g n i f i c a n ta s s o c i a -
tion signals with decline of FEV1 (Table 3), allelic dose effect
revealed no consistent results of decline of FEV1 between
rs192808 and CACNG6_BL1_ht6 due to the small number
of rare alleles (R/R), therefore further replication studies are
needed for a correct association. Among polymorphisms in
the CACNG6 gene, the rs192808 polymorphism in intronic
region showed a highly significant signal. It has also been
Table 1 Clinical profiles of aspirin intolerance asthma
and control subjects
Clinical profile AIA ATA
Number of subjects (n) 102 429
Age [year, mean (range)] 42.76 (18.66-
72.73)*
47.30 (15.40-
77.88)
Sex (n, male/female) 37/65 147/282
Smoker (current smoker/exsmoker)
(%)
21.36 (13.59/
7.77)*
30.07 (12.35/
17.72)
Height [cm, mean (range)] 161.70 ± 9.91 160.42 ± 8.39
Weight (kg) 61.64 ± 10.39 63.40 ± 10.97
Body mass index (kg/m
2) 23.56 ± 3.37* 24.58 ± 3.39
% decline of FEV1 by aspirin
provocation
33.59 ± 13.42** 3.54 ± 4.85
Blood eosinophil (%) 6.65 ± 5.78 6.03 ± 5.92
FEV1 (% predicted) 85.10 ± 16.41* 91.66 ± 16.87
PC20 methacholine (mg/ml) 4.26 ± 7.62* 6.91 ± 8.90
Total IgE (IU/ml) 415.74 ± 714.70 361.00 ± 607.56
Positive rate of skin test (%) 48.04 57.81
Age indicates a first medical examination. AIA, aspirin-intolerant asthma; ATA,
aspirin-tolerant asthma.
*P < 0.05; **P < 0.0001 compared to ATA control.
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Page 4 of 7found that CACNG6 has three transcripts. Thus, to predict
role of rs192808, we performed GeneSplicer http://www.
cbcb.umd.edu/software/GeneSplicer and EMBL-EBI splice
site prediction tool http://www.ebi.ac.uk/asd-srv/wb.cgi?
method=2 to know whether rs192808 could be located in
splicing association site [29]. However, results showed that
the rs192808 was not located in any splicing-related site
such as donor site (5′ boundary), acceptor site (3′ boundary)
and branch point. In addition, the functionality of other
SNPs that were in LD with rs192808 was analyzed. How-
ever, results from the Signal Scan program http://www-
bimas.cit.nih.gov/molbio/signal/ revealed that CACNG6
rs251850 in promoter region was not a transcriptional ele-
ment, and three intronic SNPs (rs4806481, rs158196,
rs158199) were not predicted as splicing-related sites.
A previous study has reported that some SNPs located
deep in intronic region can create new transcription factor
binding site [30]. Thus, we further performed TFSEARCH
http://www.cbrc.jp/research/db/TFSEARCH.html using
bioinformatical software to predict whether rs192808 can
create transcription binding site. However, results showed
that the location of rs192808 is not in the transcription fac-
tor binding site. Even if these results suggest that rs192808
may not affect the function of CACNG6, previous studies
reported that sometimes allelic variants in intron can lead
to the onset of human diseases due to alterations in the
expression level of mRNA caused by creating potential
aberrant splice sites [31,32]. Moreover, additional tran-
scriptional isoforms of the CACNG6 gene have been dis-
covered from the Mammalian Gene Collection (MGC)
Program [33] as shown in the Ensembl Genome Browser
http://www.ensembl.org/index.html (Additional files 3,
Figure S1). Therefore, findings from our study on the sig-
nificant association between rs192808 and AIA needs to be
replicated and/or further analyzed in order to understand
its detailed function in the mechanism of AIA.
S i n c et h e r ei sap o s s i b i l i t yt h a tCACNG6 SNPs are in LD
with functional SNP(s) that is/are located in a different gene
Figure 1 Gene maps and haplotypes of the CACNG6 gene. Schematic physical map, haplotypes and LD plot of CACNG6. (A) Polymorphisms
identified in CACNG6. Coding exons are marked by shaded blocks and 3’-untranslated region (UTR) by white blocks. The LD coefficients (r
2) are
based on the genotypes of Korean samples. (B) Haplotypes of CACNG6 in the Korean population. Only those with frequencies over 0.05 are
shown in Table 2 and 3. (C) LD coefficients (|D’|) among the selected SNPs based on the genotypes of whole study subjects in this study. (D) LD
coefficients (|D’|) in AIA and ATA.
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Page 5 of 7in the nearby region, we further analyzed the LD near
CACNG6 in Asian populations (Japanese and Chinese) from
the International HapMap Project. However, the CACNG6
gene showed no LD with other nearby genes (Additional
files 4, Figure S2). On the other hand, although minor allele
frequencies of 8 SNPs validated in Korean asthmatics were
similar to those of Asian populations (Chinese and Japa-
nese), significant differences were detected from other popu-
lations especially in rs158196, rs1581199, rs192808,
rs450227, rs2291068,a n drs459247 (Additional files 2, Table
S2). When comparing LDs on 8 SNPs of CACNG6 among
Korean asthmatic patients and other populations (Additional
file 5, Figure S3), albeit non-asthmatic Korean population
has not determined, it can be assumed that a different LD
status of the asthmatics may affect AIA and/or asthma-
related phenotypes at least in a Korean population. More-
over, although replications and functional studies are
needed, rs192808 and CACNG6_BL1_ht6 could be genetic
markers of AIA susceptibility.
Conclusions
Although replication for the associations is required in
an independent study cohort to validate our findings,
this study showed that the genetic polymorphisms of
CACNG6 might be associated with risk of AIA at least
in a Korean population, providing a new link between
voltage-dependent calcium channel and aspirin hyper-
sensitivity in asthmatics. Further functional and replica-
tion studies elsewhere are needed to identify the roles of
the polymorphisms of the gene.
Additional material
Additional file 1: Regression analysis between SNPs and haplotypes
of CACNG6 in patients with AIA only. Results of regression analysis in
AIA patients only
Additional file 2: Allele information in other population for CACNG6.
Allele frequencies of CACNG6 polymorphisms among Korean and other
populations
Additional file 3: Three isoforms of CACNG6. Three different types of
the CACNG6 gene transcripts are found from the Ensembl Genome
Browser http://www.ensembl.org/index.html.
Additional file 4: LD plot nearby CACNG6. LD blocks nearby CACNG6
based on Asian populations (Japanese and Chinese) show no LD
between CACNG6 and near genes. (A) LD blocks of near genes and
CACNG6. Data for LD map is obtained from the International HapMap
project. (B) LD block of the CACNG6 gene.
Additional file 5: LDs of CACNG6 polymorphisms among populations.
Comparison of LDs of CACNG6 between Korean asthmatics and other
populations. (A) Korean asthmatics. (B) Korean AIA. (C) Korean ATA. (D)
Caucasian. (E) Asians including Japanese and Chinese. (F) Africans
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CACNG6_BL2_ht1 153 (11.09 ± 15.38) 290 (8.70 ± 11.28) 149 (8.37 ± 14.19) 0.12 0.06 0.50
CACNG6_BL2_ht2 301 (8.17 ± 12.70) 240 (10.55 ± 13.87) 51 (9.34 ± 12.78) 0.09 0.03 0.97
CACNG6_BL2_ht3 442 (9.37 ± 13.28) 145 (8.72 ± 12.92) 5 (11.80 ± 18.75) 0.51 0.44 0.75
CACNG6_BL2_ht4 515 (9.12 ± 13.08) 76 (9.99 ± 14.29) 1 (8.00) 0.86 0.83 0.78
C/C, common allele/common allele; C/R, common allele/rare allele; R/R, rare allele/rare allele;
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